New customer reference data survey looks at the current state of customer reference data within life sciences across Europe.
A new customer reference data survey from Veeva Systems looks at the current state of customer reference data within life sciences across Europe through the opinions and experiences reported by commercial data owners.
The Veeva 2020 European Customer Data Survey shows that the quality and integration of data need to be significantly improved. Some of the key findings include:
• Most (89%) say that customer data quality is a significant challenge for the businesses they support, with 41% in strong agreement with this statement.
• Over two-thirds of respondents (68%) report that their organization has customer data in multiple systems.
• 91% of respondents say that their organisation views customer reference data as a global strategic asset.
• Organizations are changing their approach to customer data, with 78% of respondents reporting that they are undertaking or planning a customer data enhancement initiative.
• Top data enhancement initiatives include improving data access and field force effectiveness (77%), gaining a 360-degree view of customers (77%), and enhancing data quality for accurate reporting /analytics (71%).
“There is increasing urgency throughout the industry to improve the accuracy of customer reference data to better support digital transformation efforts,” commented Rebecca Silver, general manager, Veeva OpenData. “Having a complete, full picture of the customer is key to getting the right insights and accelerating digital engagement.”
The majority of respondents (90%) say that field teams are challenged with aging and incomplete data. Most (89%) say that customer data quality is a significant challenge. Issues with poor data quality are likely driving data enhancement programs, with 88% citing data improvement as a top priority for their organization.
Over two-thirds have data that exists in multiple, unintegrated systems. This lack of integration makes it harder to access customer data. More than three-quarters cite difficulty matching all channels of data to get a single view of their customer interactions. Majorities (55%) report dissatisfaction enabling reps to engage new HCPs with real-time access to customer data.
Respondents show a lack of confidence in their organizations’ ability to manage customer reference data and implement successful data management strategies. More than half (57%) say their organizations lack an efficient data governance model and only 10% of companies surveyed strongly agree they are satisfied with their data governance.
Quality data is key to field performance, notes Veeva, “which explains why the majority of respondents (77%) are focused on better data access to improve sales force effectiveness.”
See further information here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.